抗CD90单克隆抗体在治疗黑色素细胞瘤中的基础研究

Therapeutic Effects of Anti-CD90 Monoclonal Antibody in Melanoma

目的:探讨应用抗CD90单克隆抗体治疗黑色素细胞瘤的可行性及相关机制。方法:首先通过流式细胞检测技术,探究抗CD90单克隆抗体是否能在体外诱导B16细胞凋亡。之后,通过向C57BL/6J小鼠皮下注射B16细胞建立小鼠黑色素瘤模型,并给予抗CD90单克隆抗体治疗,评价其抗肿瘤的治疗效果。同时,应用免疫组织化学的方法观察小鼠成瘤组织中新生血管的形成和分布情况,统计肿瘤中微血管密度进行比较。结果:抗CD90单克隆抗体在体外不能直接诱导B16细胞凋亡,但抗CD90单克隆抗体能够抑制小鼠黑色素瘤的原位生长(p=0.049);使用免疫组织化学染色法对肿瘤组织切片进行染色,发现经过抗体治疗的小鼠成瘤组织中的新生血管明显减少,治疗组和对照组肿瘤组织的微血管密度存在显著性差异(p=0.011)。结论:抗CD90单克隆抗体能够通过抑制肿瘤组织中新生血管的形成影响黑色素瘤的发生发展,从而达到治疗黑色素瘤的效果。

Objective： To investigate the feasibility and mechanism of anti-CD90 monoclonal antibody in the treatment of melanoma. Methods： In this study, the possibility of anti-CD90 monoclonal antibody to induce the B16 cell line apoptosis in vitro was analyzed by flow cytometry firstly. Afterwards, the murine melanoma model was established by subcutaneously injecting B16 cells into C57BL / 6J mice, then evaluated the anti-tumor effect of anti-CD90 monoclonal antibody by comparing the size and weight of the tumors. The formation and distribution of neovascularization in tumor tissues were detected by immunohistochemistry, for comparing the microvascular density in the control group and the therapy group. Results： Although anti-CD90 monoclonal antibody could not directly induce the apoptosis of B16 cells, it could inhibit the progress of melanoma in mice in situ （p=0.049）, and the neovascularization in therapy group was significantly reduced. The t-test results showed that there was a significant difference in microvascular density between the treatment group and the control group （p=0.011）. Conclusions： Anti-CD90 monoclonal antibody can inhibit the development of melanoma by inhibiting the formation of neovascularization in tumor tissue, so as to achieve the effect of melanoma treatment.